Recent clinical research in people with (MND (ALS) reported that two nanocurcumin
1)Nanocurcumin + 2) Alpha lipoic acid
· reduced pain and inflammation
· improved quality of life
in people with MND (ALS)
While they are not a cure and should not replace medical treatment, human studies in people with migraine have shown encouraging results, particularly when highly bioavailable forms are used.
We conducted a 12-month, double-blind, randomized, placebo-controlled trial at a neurological referral center in Iran. Eligible patients with a definite or probable ALS diagnosis were randomly assigned to receive either nanocurcumin (80 mg daily) or placebo in a 1:1 ratio. A computerized random number generator was used to prepare the randomization list. All patients and research investigators were blinded to treatment allocation. The primary outcome was survival, and event was defined to be death or mechanical ventilation dependency. Analysis was by intention-to-treat and included all patients who received at least one dose of study drug. A total of 54 patients were randomized to receive either nanocurcumin (n = 27) or placebo (n = 27). After 12 months, events occurred in 1 patient (3.7%) in the nanocurcumin group and in 6 patients (22.2%) in the placebo group. Kaplan-Meier analysis revealed a significant difference between the study groups regarding their survival curves (p = 0.036). No significant between-group differences were observed for any other outcome measures. No serious adverse events or treatment-related deaths were detected. No patients withdrew as a result of drug adverse events. The results suggest that nanocurcumin is safe and might improve the probability of survival as an add-on treatment in patients with ALS, especially in those with existing bulbar symptoms. Future studies with larger sample sizes and of longer duration are needed to confirm these findings.
A small, 6 month study of people with ALS (mostly limb onset, but some bulbar onset) examined the effect of a food supplement containing
Alpha lipoic acid +
Vitamin B1
Vitamin B2
Vitamin B12
Most of these people with ALS were taking iluzole or edaravone.
The data showed that there was no decrease in quality of life, fatigue or depression during the six month trial, in fact there was a significant improvement in these measurements.
Therefore Alpha lipoic acid + vitamin b1, b2 and B12 may be worth supplementing for people with MND (ALS)
